Stéphane Bancel, Moderna CEO (Lenin Nolly/NurPhoto via AP Images)
September 12, 2024 06:00 AM EDTUpdated 09:33 AM
R&D

Mod­er­na plans $1.1B in R&D and pro­gram cuts, de­lays break-even point to 2028

Andrew Dunn

Senior Biopharma Correspondent

Stéphane Ban­cel has re­lent­ed to Wall Street’s de­sire for cost-cut­ting and rein­ing in Mod­er­na’s pipeline.

To kick off its an­nu­al R&D day in New York …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Rock­et shares promis­ing long-term re­sults from rare heart dis­ease gene ther­a­py in small study

FDA of­fers more guid­ance on de­vel­op­ing cell and gene ther­a­pies

A rare neu­ro­log­i­cal dis­ease is Sage’s last, best hope af­ter fail­ures in de­pres­sion

Neu­ro­gene pa­tient had life-threat­en­ing side ef­fect in Rett syn­drome study

No­var­tis strikes ra­dio­phar­ma deal with Ra­tio worth up to $745M

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times